APA (7th ed.) Citation

Y, S., L, V., A, C., JJWM, J., EFM, P., A, D., . . . NMA, B. (2025). Benefits and Limitations of Real-World Patient-Reported Toxicity Symptom Monitoring for Guidelines and Care, as Perceived by Patients, Clinicians, and Guideline Developers. Cancer medicine, 14(8), e70880. https://doi.org/10.1002/cam4.70880

Chicago Style (17th ed.) Citation

Y, Smit, Verweij L, Currie A, Janssen JJWM, Posthuma EFM, Dekker A, Hermens RPMG, and Blijlevens NMA. "Benefits and Limitations of Real-World Patient-Reported Toxicity Symptom Monitoring for Guidelines and Care, as Perceived by Patients, Clinicians, and Guideline Developers." Cancer Medicine 14, no. 8 (2025): e70880. https://doi.org/10.1002/cam4.70880.

MLA (9th ed.) Citation

Y, Smit, et al. "Benefits and Limitations of Real-World Patient-Reported Toxicity Symptom Monitoring for Guidelines and Care, as Perceived by Patients, Clinicians, and Guideline Developers." Cancer Medicine, vol. 14, no. 8, 2025, p. e70880, https://doi.org/10.1002/cam4.70880.